Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

@article{Schroth2009AssociationBC,
  title={Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.},
  author={Werner Schroth and Matthew P. Goetz and Ute Hamann and Peter A. Fasching and Michael Schmidt and Stefan Winter and Peter Fritz and W. Simon and Vera J. Suman and Matthew Ames and Stephanie L. Safgren and Mary J. Kuffel and Hans Ulrich Ulmer and Julia Bol{\"a}nder and Reiner Strick and Matthias W. Beckmann and Heinz Koelbl and Richard M. Weinshilboum and James N. Ingle and Michel Eichelbaum and Matthias Schwab and Hiltrud Brauch},
  journal={JAMA},
  year={2009},
  volume={302 13},
  pages={1429-36}
}
CONTEXT The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme. OBJECTIVE To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen. DESIGN, SETTING, AND PATIENTS Retrospective analysis of German and US… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 213 extracted citations

Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.

Expert opinion on drug metabolism & toxicology • 2011
View 4 Excerpts
Highly Influenced

Genomics and pharmacogenomics of breast cancer: current knowledge and trends.

Asian Pacific journal of cancer prevention : APJCP • 2011
View 7 Excerpts
Highly Influenced

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis

Cancer Chemotherapy and Pharmacology • 2013
View 9 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer

JF Forbes, J Cuzick, +3 authors M Baum
Lancet Oncol • 2008
View 3 Excerpts
Highly Influenced

Comparison of CYP2D6 genotyping methods in breast cancer patients treated with tamoxifen–MALDI TOF-MS and microarray-based by Amplichip CYP450 test

W Schroth, U Haman, PA. Fasching
Presented at: Joint Cold Spring Harbor Laboratory Wellcome Trust Conference; September • 2009
View 1 Excerpt

Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.

Annals of oncology : official journal of the European Society for Medical Oncology • 2008

CYP2D6 genotyping and the pharmacogenetics of tamoxifen.

Clinical advances in hematology & oncology : H&O • 2008

Similar Papers

Loading similar papers…